Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Circulating Tumor DNA
/ blood
Female
Glioblastoma
/ blood
High-Throughput Nucleotide Sequencing
/ methods
Humans
Longitudinal Studies
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Mutation
Pilot Projects
Prognosis
Prospective Studies
Survival Rate
Tumor Burden
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2020
15 01 2020
Historique:
received:
02
08
2019
revised:
19
09
2019
accepted:
28
10
2019
pubmed:
2
11
2019
medline:
2
10
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
The clinical utility of plasma cell-free DNA (cfDNA) has not been assessed prospectively in patients with glioblastoma (GBM). We aimed to determine the prognostic impact of plasma cfDNA in GBM, as well as its role as a surrogate of tumor burden and substrate for next-generation sequencing (NGS). We conducted a prospective cohort study of 42 patients with newly diagnosed GBM. Plasma cfDNA was quantified at baseline prior to initial tumor resection and longitudinally during chemoradiotherapy. Plasma cfDNA was assessed for its association with progression-free survival (PFS) and overall survival (OS), correlated with radiographic tumor burden, and subjected to a targeted NGS panel. Prior to initial surgery, GBM patients had higher plasma cfDNA concentration than age-matched healthy controls (mean 13.4 vs. 6.7 ng/mL, Plasma cfDNA may be an effective prognostic tool and surrogate of tumor burden in newly diagnosed GBM. Detection of somatic alterations in plasma is feasible when samples are obtained prior to initial surgical resection.
Identifiants
pubmed: 31666247
pii: 1078-0432.CCR-19-2533
doi: 10.1158/1078-0432.CCR-19-2533
pmc: PMC6980766
mid: NIHMS1541822
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
397-407Subventions
Organisme : NCI NIH HHS
ID : K12 CA076931
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001878
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Oncotarget. 2017 Jun 27;8(26):43180-43191
pubmed: 28574818
PLoS Genet. 2016 Jul 18;12(7):e1006162
pubmed: 27428049
Oncotarget. 2016 Mar 1;7(9):9707-17
pubmed: 26848768
Neurology. 2012 Oct 16;79(16):1693-8
pubmed: 23035067
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Sci Rep. 2018 Apr 26;8(1):6553
pubmed: 29700310
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Clin Cancer Res. 2018 Aug 1;24(15):3528-3538
pubmed: 29776953
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
CNS Oncol. 2019 Jun;8(2):CNS34
pubmed: 30855176
J Egypt Natl Canc Inst. 2016 Dec;28(4):235-242
pubmed: 27634416
Neuro Oncol. 2018 Oct 9;20(11):1525-1535
pubmed: 29897562
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
JAMA Oncol. 2016 Aug 1;2(8):1014-22
pubmed: 27055085
Eur J Cancer. 2018 Jan;88:1-9
pubmed: 29175734
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520
pubmed: 30733593
J Transl Med. 2018 Nov 6;16(1):300
pubmed: 30400802
Cancer Res. 1977 Mar;37(3):646-50
pubmed: 837366
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Acta Anaesthesiol Scand. 2017 Oct;61(9):1084-1094
pubmed: 28766696
Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81
pubmed: 28786531
Clin Cancer Res. 2017 Sep 15;23(18):5416-5425
pubmed: 28576867
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859
pubmed: 30322880
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Clin Cancer Res. 2018 Sep 15;24(18):4437-4443
pubmed: 29567812
Mol Cancer Ther. 2019 Jan;18(1):196-203
pubmed: 30301865
N Engl J Med. 2018 Nov 01;379(18):1754-1765
pubmed: 30380390
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
J Clin Oncol. 2018 Feb 20;36(6):543-553
pubmed: 29298117
Cancer Res. 2019 Jan 1;79(1):220-230
pubmed: 30389699
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385733
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Clin Cancer Res. 2016 Dec 1;22(23):5772-5782
pubmed: 27601595
JAMA Oncol. 2019 Feb 1;5(2):173-180
pubmed: 30325992
Clin Cancer Res. 2017 Jan 1;23(1):116-123
pubmed: 27993964
Mol Cancer Res. 2016 Oct;14(10):898-908
pubmed: 27422709
BMC Med Imaging. 2015 Jun 16;15:19
pubmed: 26076957
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819
pubmed: 29615461
Eur J Cancer. 2017 Nov;86:349-357
pubmed: 29078173
Lancet Oncol. 2019 May;20(5):728-740
pubmed: 30952559